Table 2.
Progression and infusion-related reactions | |
---|---|
Progression (%) | 72.2 |
Rapid Progression (%) | 19.4 |
Median days to progression (range) | |
Overall | 158 (71–367) |
Rapid progression group | 104 (71–111) |
Non-rapid progression group | 168 (124–367) |
Infusion-related reaction (%) | 8.3 |